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Abstract
Background: Aetiology and outcomes of sepsis in sub-Saharan Africa (sSA) are poorly described; we performed a
systematic review and meta-analysis to summarise the available data.
Methods: Systematic searches of PubMed and Scopus were undertaken to identify prospective studies recruiting
adults (> 13 years) with community-acquired sepsis in sSA post-2000. Random effects meta-analysis of in-hospital
and 30-day mortality was undertaken and available aetiology data also summarised by random effects meta-analysis.
Results: Fifteen studies of 2800 participants were identified. Inclusion criteria were heterogeneous. The majority of
patients were HIV-infected, and Mycobacterium tuberculosis was the most common cause of blood stream infection
where sought. Pooled in-hospital mortality for Sepsis-2-defined sepsis and severe sepsis was 19% (95% CI 12–29%)
and 39% (95% CI 30–47%) respectively, and sepsis mortality was associated with the proportion of HIV-infected
participants. Mortality and morbidity data beyond 30 days were absent.
Conclusions: Sepsis in sSA is dominated by HIV and tuberculosis, with poor outcomes. Optimal antimicrobial
strategies, including the role of tuberculosis treatment, are unclear. Long-term outcome data are lacking.
Standardised sepsis diagnostic criteria that are easily applied in low-resource settings are needed to establish
an evidence base for sepsis management in sSA.
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Introduction
Sepsis, defined most recently as a syndrome of life-
threatening organ dysfunction due to a dysregulated host
response to infection [1], is common worldwide and carries
a high mortality: recent estimates suggest 19.4 million
yearly cases and 5.3 million deaths [2]. In high-income
settings, outcomes are improving, due in part to a com-
prehensive application of an expanding evidence base for
early recognition, rapid administration of appropriate
antimicrobials, and aggressive fluid resuscitation paired
with intensive monitoring of physiology and provision for
organ support [3, 4]. In low-resource settings including
sub-Saharan Africa (sSA), data are limited but some studies
have identified high mortality [5]. It is clear that sepsis
protocols developed in high-income settings should not
simply be exported unchanged to sSA: aggressive fluid
resuscitation has been shown to be harmful in one rando-
mised controlled trial (RCT) in adults and one in children
[6, 7] and caution is warranted before proposing fluid
management guidelines for sSA.
The paucity of data presents challenges in proposing
sepsis management specific to sSA. Firstly, defining
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sepsis for clinical practice or research is problematic.
Recent Sepsis-3 guidelines (the third iteration of the
international consensus diagnostic definitions of sepsis)
suggest operationalising the diagnosis of sepsis using
the sequential organ failure assessment (SOFA) score
[1]. Applying this score to resource-limited settings
is difficult due to patchy availability of variables,
particularly laboratory values. The bedside “quick
SOFA” (qSOFA) score can identify patients at a
higher risk of death, but is a screening rather than a
diagnostic tool [8–10]. Previous iterations of the
guidelines defined sepsis using the systemic inflam-
matory response score (SIRS) in the presence of a
suspicion of infection, with severe sepsis defined by
the addition of organ dysfunction [11], but SIRS,
while applicable at the bedside, has been criticised
for its lack of discriminatory power [12].
Secondly, the optimal clinical management of sepsis
in sSA is unknown. Early, appropriate antimicrobials
improve outcomes in high-income settings [13, 14],
and it is likely that this is a transferable recommen-
dation to sSA. Certainly, it seems unlikely that rapid
administration of antimicrobials will adversely affect
outcomes in the way aggressive fluid resuscitation
does and may represent an important first step in
improving outcomes. However, in the absence of
robust sepsis aetiology data, what constitutes “appro-
priate” empirical antimicrobial chemotherapy remains
an open question in sSA. Tuberculosis and malaria
certainly play an important role, and arboviral in-
fections, bacterial zoonoses, and HIV opportunistic
infections may also be important [15–19].
Finally, sepsis outcomes in sSA are heterogeneous
between studies [20, 21] and longer-term follow-up is
sparse. Post-discharge sepsis mortality in high-income
settings is significant (11–43% at 1 year) as is mor-
bidity [22], but post-discharge outcomes in sSA are
unknown.
We therefore performed a systematic review and
meta-analysis of clinical studies from sSA with three aims:
to describe the sepsis definitions used, the aetiology of
infection, and clinical outcomes.
Methods
The protocol of this systematic review was pre-registered
on PROSPERO, number CRD42019123589, and follows
the PRISMA guidelines.
Searches
Searches of PubMed and Scopus were undertaken using the
search terms shown in Box 1, in all fields. Identified ab-
stracts were exported into Endnote X7.8 (Thomson Reuters,
USA) and screened against inclusion and exclusion criteria.
Inclusion criteria were as follows: prospective cohort
studies, non-randomised intervention studies, or rando-
mised controlled trials recruiting adults (> 13 years) with
community-acquired sepsis from sSA, for which it was
possible to disaggregate a total number of adults with sep-
sis and was possible to extract aetiology or outcome data.
Any study-defined definition of sepsis was accepted. Retro-
spective studies were excluded due to a high risk of bias:
we were concerned that in low-resource settings medical
records can often be incomplete and this could introduce
significant bias. Exclusion criteria were studies published
before 2000 and studies recruiting preselected populations,
e.g. puerperal sepsis. There was no language restriction.
Abstracts were screened by two authors (JL and JR)
and disagreements resolved by consensus. All included
abstracts underwent independent full-text review by the
same authors, and the inclusion and exclusion criteria
were again applied, and disagreements resolved by con-
sensus. Data were extracted onto an Excel spreadsheet
(Microsoft, USA) for further analysis: study first author,
years of recruitment, inclusion and exclusion criteria,
number of patients recruited and demographics (inclu-
ding age, proportion of HIV-infected participants, and
CD4 count values), in-hospital, 28- or 30-day mortality,
and details of any aetiologic investigations undertaken.
Quality assessment
A modified Newcastle-Ottawa scale was used to assess
risk of bias in the domains of selection, comparability,
and outcome (full scale shown in Additional file 1) This
was completed by two authors independently, and
disagreements were resolved by consensus to provide a
single assessment of each study incorporating all domains.
Statistical analysis
Because of concerns about meta-analysis of propor-
tions on very heterogeneous populations, we planned
Box 1: Systematic review search terms
Sepsis AND ((Angola OR Benin OR Botswana OR Burkina Faso OR
Burundi OR Cameroon OR Cape Verde OR Central African Republic
OR Chad OR Comoros OR Republic of the Congo OR Congo
Brazzaville OR Democratic republic of the Congo OR Cote d’Ivoire
OR Djibouti OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon
OR The Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya
OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR
Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR
Nigeria OR Reunion OR Rwanda OR Sao Tome and Principe OR
Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa
OR Sudan OR Swaziland OR Eswatini OR Tanzania OR Togo OR
Uganda OR Western Sahara OR Zambia OR Zimbabwe) OR Africa)
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meta-analysis of outcome stratified by inclusion criteria
where possible: Sepsis-2 sepsis, Sepsis-2 severe sepsis, and
Sepsis-3 sepsis, if available. Mortality was presented as a
simple proportion with exact binomial confidence inter-
vals, and pooled mortality estimates were calculated using
generalised linear mixed models (a normal-binomial
model) using the packages meta and lme4 in R. For inter-
ventional studies, the outcomes in the usual care arm of
the study only were included in these estimates. Hetero-
geneity was quantified with τ2, I2, and Cochran’s Q test.
Exploratory meta-regression was undertaken to explore
heterogeneity by including covariates as fixed effects
(year of recruitment, proportion of patients infected
with HIV, and median age) and testing for improved
model fit by likelihood ratio testing of nested models. A
p value of < 0.05 was considered a statistically signifi-
cantly improved fit. Bubble plots of the meta-
regressions were produced with 95% confidence inter-
vals obtained from 1000 bootstrap replicates. Summary
estimates of 28- and 30-day mortality, where available,
were considered together and were presented in the same
way. Pooled prevalence estimates of malaria, blood-
stream infection (BSI), and Mycobacterium
tuberculosis bloodstream infection (MTB-BSI) were
calculated using random effects meta-analysis as above.
For these aetiology analyses, we included all studies, re-
gardless of sepsis definition, and included both usual care
and intervention arms of RCTs. All analysis was carried
out in R V3.5.1 (R Foundation for Statistical Computing,
Vienna, Austria).
Results
The abstract search yielded 3951 unique records on 17
July 2018 (Fig. 1), of which 3902 were excluded. After
screening 49 full-text articles, 15 were retained. One
article was a secondary analysis of the aetiology of a
previously presented cohort [23], meaning 15 articles
were included, reporting on 14 prospective clinical
studies from nine centres in six countries. These in-
cluded 11 cohort studies [5, 20, 21, 24–31], two rando-
mised controlled trials [32, 33], and one before-after
interventional trial [34] (Table 1).
Data from 2800 unique participants were eligible
(Table 1). Data from some participants were included in
two or more separate publications, but we were able to ex-
tract aggregate data such that no participant contributed
Fig. 1 Summary of studies screened and included
Lewis et al. Critical Care          (2019) 23:212 Page 3 of 11
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
in
cl
ud
ed
st
ud
ie
s
A
ut
ho
r
an
d
pu
bl
ic
at
io
n
ye
ar
Ye
ar
s
re
cr
ui
tin
g
St
ud
y
ty
pe
C
ou
nt
ry
N
ce
nt
re
s
C
en
tr
e
ty
pe
In
c.
cr
ite
ria
n
M
al
e
se
x
A
ge
H
IV
in
fe
ct
ed
M
ed
ia
n
C
D
4
μL
−
1
Ja
co
b
et
al
.2
00
9
[5
]
20
06
C
oh
or
t
U
ga
nd
a
2
Re
fe
rr
al
SI
Is
ev
er
e
se
ps
is
38
2
15
6/
38
2
(4
1%
)
35
32
0/
38
2
(8
5%
)
52
N
ad
jm
et
al
.2
01
2
[2
5]
20
07
C
oh
or
t
Ta
nz
an
ia
1
D
is
tr
ic
t
Fe
ve
r
an
d
on
e
se
ve
rit
y
cr
ite
ria
19
8
67
/1
98
(3
4%
)
37
69
/1
80
(3
8%
)
N
R
Ja
co
b
et
al
.2
01
2
[3
4]
a
an
d
M
oo
re
et
al
.2
01
8
[2
3]
20
08
–2
00
9
Be
fo
re
-a
ft
er
U
ga
nd
a
2
Re
fe
rr
al
SI
Is
ev
er
e
se
ps
is
42
6
20
7/
42
6
(4
9%
)
34
36
2/
42
6
(8
5%
)
63
W
ai
tt
et
al
.2
01
5
[2
6]
20
08
–2
00
9
C
oh
or
t
M
al
aw
i
1
Re
fe
rr
al
SI
Is
ep
si
s
21
3
87
/2
13
(4
1%
)
30
16
1/
21
3
(7
6%
)
N
R
Ss
ek
ito
le
ko
et
al
.2
01
1
[2
7]
a
20
09
C
oh
or
t
U
ga
nd
a
1
Re
fe
rr
al
SI
Is
ep
si
s
96
19
3/
41
8b
(4
6%
)
35
33
1/
41
8b
(8
3%
)
N
R
Ss
ek
ito
le
ko
et
al
.2
01
1
[2
8]
20
09
C
oh
or
t
U
ga
nd
a
1
Re
fe
rr
al
SI
Is
ep
si
s
15
0
94
/1
50
(6
3%
)
35
96
/1
50
(6
4%
)
N
R
C
hi
m
es
e
et
al
.2
01
2
[2
1]
20
10
C
oh
or
t
Za
m
bi
a
1
Re
fe
rr
al
SI
Is
ep
si
s
16
1
79
/1
61
(4
9%
)
39
11
0/
13
8
(8
0%
)
N
R
A
nd
re
w
s
et
al
.2
01
4
[3
5]
20
12
RC
T
Za
m
bi
a
1
Re
fe
rr
al
SI
Is
ev
er
e
se
ps
is
11
2
58
/1
09
(5
3%
)
35
88
/1
09
(8
1%
)
N
R
A
um
a
et
al
.2
01
3
[2
9]
20
12
C
oh
or
t
U
ga
nd
a
1
Re
fe
rr
al
SI
Is
ep
si
s
21
6
10
6/
21
6
(4
9%
)
32
12
2/
21
6
(5
6%
)
N
Re
A
nd
re
w
s
et
al
.2
01
7
[3
3]
20
12
–2
01
3
RC
T
Za
m
bi
a
1
Re
fe
rr
al
SI
Is
ev
er
e
se
ps
is
20
9
11
7/
20
9
(5
6%
)
36
18
7/
20
9
(9
0%
)
66
H
us
on
et
al
.2
01
4
[2
0]
20
12
–2
01
3
C
oh
or
t
G
ab
on
1
Re
fe
rr
al
SI
Is
ep
si
s
10
7
N
A
34
26
/1
07
(2
4%
)
16
8
Se
bo
xa
et
al
.2
01
5
[3
0]
20
12
–2
01
3
C
oh
or
t
Et
hi
op
ia
1
Re
fe
rr
al
SI
Is
ep
si
s
29
2
15
1/
29
2
(5
2%
)
27
40
/2
09
(1
9%
)
N
R
Ru
dd
et
al
.2
01
7
[3
1]
20
13
C
oh
or
t
U
ga
nd
a
1
D
is
tr
ic
t
SI
Is
ep
si
s
20
11
/2
0
(5
5%
)
32
6/
20
(3
0%
)
N
R
A
m
ir
et
al
.2
01
6
[2
4]
20
14
–2
01
5
C
oh
or
t
U
ga
nd
a
1
Re
fe
rr
al
SI
Is
ev
er
e
se
ps
is
21
8
11
0/
21
8
(5
0%
)
35
12
5/
21
8
(5
7%
)
78
RC
T
ra
nd
om
is
ed
co
nt
ro
lle
d
tr
ia
l,
SI
IS
ep
si
s-
2
de
fin
iti
on
(e
.g
.S
II
se
ps
is
is
co
ns
is
te
nt
w
ith
Se
ps
is
-2
de
fin
iti
on
).
a T
he
se
st
ud
ie
s
al
so
pr
es
en
t
da
ta
fr
om
Ja
co
b
et
al
.[
5]
—
on
ly
ne
w
da
ta
is
in
cl
ud
ed
in
th
is
ta
bl
e
ro
w
.
b
D
is
ag
gr
eg
at
ed
da
ta
ar
e
no
t
gi
ve
n
fo
r
th
e
in
cl
ud
ed
96
pa
tie
nt
s;
H
IV
pr
ev
al
en
ce
fo
r
th
e
to
ta
lc
oh
or
t
is
sh
ow
n
Lewis et al. Critical Care          (2019) 23:212 Page 4 of 11
data twice. Generally, the risk of bias as assessed by
the modified Newcastle-Ottawa scale was low (Add-
itional file 2). The most commonly identified areas of con-
cern were in ascertaining exposure (all studies ascertained
HIV status but 6/14 studies lacked details of HIV testing
procedures) or in comparability (5/14 studies did not test
lactate and/or provide details of enrollment physiology,
both components of the comparability domain of our
modified Newcastle-Ottawa score). The patients recruited
to the identified studies had median age ranging from 27 to
39 years and were predominantly HIV-infected: 2577/2800
patients had an available HIV status, with 1712/2577 (66%)
being HIV-infected, though HIV rates varied between
studies (median 70% [IQR 42.5–82.5%], Table 1).
The majority of studies recruited patients using a modi-
fied Sepsis-2 definition of sepsis or severe sepsis, though
definitions were heterogeneous (primary study inclusion
and exclusion criteria are shown in Additional file 3). SIRS
was used to define sepsis or severe sepsis in 13/14 cohorts,
but the definition of SIRS itself was variable. Six of the 13
studies using SIRS did not use the white cell count
criterion because of resource limitations, and four diffe-
rent temperature thresholds were used in the 13 studies to
define hypo- or hyperthermia.
Of the 13 studies using SIRS as a component of in-
clusion criteria, 8/13 recruited patients with a definition
compatible with Sepsis-2 sepsis (SIRS plus suspected or
confirmed infection, 1255 patients in total) and 5/13 stu-
dies recruited a population compatible with Sepsis-2 se-
vere sepsis of SIRS plus organ dysfunction (1347 patients
in total). A variety of organ dysfunction criteria were used
including hyperlactataemia or poor Karnofsky perform-
ance score; the most common organ dysfunction criterion
was low systolic blood pressure, applied in all five studies.
No study specifically recruited patients with septic shock,
and despite the frequent use of low systolic blood pressure
as a defining criterion for severe sepsis, only one study
[28] explicitly defined septic shock, using a definition of
hypotension (SBP < 90mmHg or MAP < 65mmHg)
refractory to 2 L of intravenous fluid administered over
2 h; 27 of 150 recruited patients fulfilled this definition.
The one study that used a non-Sepsis 2-based defi-
nition defined sepsis as fever plus one severity criterion
[25], adapted from the WHO severe malaria definitions.
Outcomes
All studies reported either in-hospital or 28-/30-day mor-
tality, apart from one retrospective of stored samples [23],
leaving 14 studies with outcome data. Of these, 11 re-
ported only in-hospital mortality, three studies reported
both 28-/30-day mortality and in-hospital mortality, and
one reported only 28-/30-day mortality. No studies re-
ported longer-term outcomes or estimates of morbidity.
We therefore pooled the outcome data from the 13
studies with outcome data that used Sepsis-2 based inclu-
sion criteria: in-hospital mortality data were available for
Sepsis-2-compatible sepsis (1159 participants from
seven studies) and severe sepsis (983 participants from
seven studies). The 28-/30-day mortality data were only
available for severe sepsis (484 patients from three studies).
Pooled estimates of Sepsis-2-defined sepsis and severe sep-
sis in-hospital mortality were 19% (95% CI 12–29%) and
39% (95% 30–47%) respectively, and pooled 28- and 30-day
Sepsis-2-defined severe sepsis mortality was 54% (95% 37–
70%), though significant between-study heterogeneity
means these summary estimates should be treated with cau-
tion (Fig. 2).
Heterogeneity was explored with meta-regression.
Proportion of HIV-infected participants was significantly
associated with inpatient mortality in studies recruiting
patients with Sepsis-2-defined sepsis when included as a
fixed-effect covariate (p = 0.006 on likelihood ratio test-
ing of nested models), but year of recruitment was not
(p = 0.06). Neither year nor proportion of HIV-infected
participants (p = 0.51 and p = 0.83) were associated with
inpatient mortality in Sepsis-2 severe sepsis studies.
Severe sepsis studies in general appeared to have higher
proportion of HIV-infected participants than studies
recruiting patients with sepsis (Fig. 3); in only one study
[26] was it possible to extract data to compare HIV
prevalence in sepsis and severe sepsis in the same study:
HIV prevalence was higher in severe sepsis in absolute
terms though numbers were small and the difference
was not statistically significant (HIV prevalence 26/32
[81%] severe sepsis vs 161/213 [76%] in sepsis, p = 0.89).
Median age was not associated with in-hospital mortality
in sepsis or severe sepsis analyses (p = 0.66 and p = 0.50
on likelihood ratio testing of nested models). In view of
the small number of studies reporting 28- or 30-day
mortality, meta-regression was not undertaken.
Outcome data on septic shock were largely absent. For
only 27 patients from the only study which defined
septic shock was it possible to extract in-hospital mor-
tality: 16/27 (59%, 95% CI 39–77%) patients died.
Aetiology
Aetiology data could be extracted from 14 studies: 11/14
reported aerobic blood culture data, 4/14 mycobacterial
blood culture and 9/14 malaria data (Fig. 4), and 1/14
reported retrospective polymerase chain reaction (PCR)
diagnostics on stored samples from Jacob et al. 2012 [34].
The data shown in Fig. 4 are those from the original Jacob
et al. 2012 study [34] and not the retrospective PCR diag-
nostics; the latter are described below. Generally, studies
performed aetiologic testing on all patients rather than
restricting to a subgroup, excepting mycobacterial blood
culture (carried out in four studies) which was restricted
to HIV-infected participants in 2/4 studies and to a
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single study site in 1/4 studies (details of aetiologic
testing availability by study are shown in Add-
itional file 4).
Diagnosis of malaria was made by smear in all studies ex-
cept the retrospective PCR study; one [29] additionally used
rapid diagnostic tests and malaria-specific PCR. Pathogenic
organisms isolated from aerobic blood culture are shown in
Additional file 5. The commonest isolated organisms were
Staphylococcus aureus (105/458 [23%]), non-typhoidal Sal-
monella (75/458 [16%]), and Streptococcus pneumoniae
(68/458 [15%]). All studies reporting blood culture results
described the microbiologic methods used but only 6/11 re-
ported external quality control procedures during the study
period.
Data on antimicrobial sensitivity patterns of the
aerobic blood culture isolates were available in only 2/11
studies. One study [5] gave limited details only, stating
that 95% of Salmonella isolates were resistant to chlo-
ramphenicol and trimethoprim-sulfamethoxazole and
that none of the Staphylococcus aureus samples were
resistant to oxacillin. The second study provided more
comprehensive details, but with very small numbers
which limit the conclusions that can be drawn; of 20
isolated Gram-negative bacilli (16 E. coli, the remainder
Klebsiella, Salmonella, and Citrobacter spp.), 9/20 (45%)
were resistant to third-generation cephalosporins, and
this was strongly associated with mortality. All patients
with third-generation cephalosporin-resistant BSI died,
compared with 1/11 (9%) of those with sensitive
infections (p < 0.0001).
One study [23] reported the results of a multiplex
PCR on cryopreserved blood specimens of 336/426
participants and identified at least one potential pathogen
in 245/336 samples, most commonly cytomegalovirus
A
B
C
Fig. 2 a In-hospital sepsis mortality. b In-hospital severe sepsis mortality. c 28- or 30-day severe sepsis mortality. In all cases, only studies using a
Sepsis-2 definition of sepsis or suspected sepsis are included. Random effects summary estimate from a generalised linear mixed model is shown
as well as measures of heterogeneity: τ2, I2, and p value from Cochran’s Q test
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(139/336 [41%]), MTB (70/336 [21%]), Plasmodium spp.
(35/336 [10%]), and Streptococcus pneumoniae (31/226
[9%]). Bacterial zoonoses or rickettsioses were uncommon
(6/336 [2%]).
Discussion
In-hospital sepsis and severe sepsis mortality in sSA is
high. We found pooled in-hospital mortality of 19%
(95% CI 12–29%) for Sepsis-2-defined sepsis and 39%
(95% 30–47%) for Sepsis-2-defined severe sepsis. Pooled
28-/30-day Sepsis-2-defined severe sepsis mortality was
54% (95% CI 37–70%). Some between-study heteroge-
neity in sepsis mortality is likely consequent upon
heterogeneous inclusion criteria, and some variability
may be explained by the proportion of participants who
are HIV-infected. Direct comparison of these mortality
estimates to outcomes in high-income settings is difficult
as estimates of sepsis mortality often derive from admin-
istrative databases and are sensitive to coding strategies.
A recent meta-analysis [2] of population level estimates
in post-2003 high-income settings estimated pooled
sepsis and severe sepsis 30-day mortality to be of 17%
(95% CI 11–26%) and 26% (95% CI 20–33%), respect-
ively. The large US patient cohort used to validate the
qSOFA score [8] (n = 74,453) found considerably lower
mortalities for sepsis (as defined by Sepsis-2), at 4%.
It is likely that the sepsis outcomes we describe for sSA
are worse than in high-income settings. The reasons for
this are likely to be multifactorial, including lack of
resources. The association of HIV status with mortality
highlights the likely role of HIV as a driver of poor sepsis
outcomes in sSA. It is also possible that delays in presen-
tation to hospital or delays in processes of care may con-
tribute to high mortality. The majority of studies we have
identified provide no data to address these hypotheses,
though there is some suggestion that presentation to care
may be delayed. In the two Zambian RCTs [33, 35], 66–
74% patients with severe sepsis were unable to walk on
admission, and this had been the case for a median of 5–
16 days; in Uganda, patients with severe sepsis had been
unwell for a median on 14 days before arrival at hospital
[24]. Data on processes of care are also largely lacking,
though delays are apparent in one study: in the “before”
arm of the before-after intervention trial in Uganda [5,
34], 49% (117/245) of patients with severe sepsis received
no antimicrobials within 6 h of presentation, and a median
of 500ml of intravenous fluids was delivered in 6 h. How-
ever, in the usual-care arm of the two Zambian RCTs
identified, mortality was high despite a prompt initiation
of care: median door-to-antibiotic time was 1.3–1.5 h and
a median 1.3–2.0 L of intravenous fluid was administered
in the first 6 h of hospital admission. Lack of critical care
facilities may play a role; again, data are largely absent,
but across the two RCTs, only 1% (3/318) of patients
were cared for on an ICU.
Of note, the 30-day mortality of severe sepsis seemed to
be higher than the in-hospital mortality, though with over-
lapping confidence intervals. The reasons for this are not
Fig. 3 Meta-regression showing the effect of varying proportions of HIV-infected participants on inpatient mortality for sepsis and severe sepsis.
95% confidence intervals generated from 1000 bootstrap replicates. Likelihood ratio testing of nested models shows that including proportion of
HIV-infected participants significantly improved model fit for sepsis (p = 0.008), but not severe sepsis (p = 0.83). Size of circle is proportional to the
number of participants with sepsis or severe sepsis
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addressed in our study, but could represent uncontrolled
primary infection, secondary infection following sepsis-
related immunosuppression, non-infection-related mor-
tality, or hospital practices such as palliative discharge of
patients with poor prognosis. None of the studies we iden-
tified characterised longer-term (post 30-day) sepsis out-
comes in sSA, and this highlights a major area for future
research in resource-limited settings. Longer-term follow-
up of patients in resource-limited settings is logistically
difficult, as is matching episodes of care in administrative
or clinical databases for individuals across fragmented and
under-resourced health systems, which would be neces-
sary to characterise sepsis outcomes from such databases;
these factors may contribute to the lack of available data.
No identified study characterised morbidity or eco-
nomic cost either to health systems or individuals,
but the combination of poor outcomes in a young
adult population—often the most economically pro-
ductive group in any society—may have significant
socio-economic implications.
A
B
C
Fig. 4 Pooled prevalence of a malaria, b bloodstream infection, and c M. tuberculosis bloodstream infection. Random effects summary estimate
from a generalised linear mixed model is shown as well as measures of heterogeneity: τ2, I2, and p value from Cochran’s Q test
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In contrast to high-income settings, the populations
recruited to the identified studies are young and predo-
minantly HIV-infected. It is likely that the high HIV preva-
lence influences the causative pathogens: the commonest
cause of bloodstream infection, when sought, was
M. tuberculosis, and non-typhoidal Salmonellae and
S. pneumoniae were also commonly isolated, both of
which have a strong association with HIV [36, 37].
Management of HIV in the critically ill in LMICs is poorly
described; this review highlights that a carefully consi-
dered strategy for HIV must be developed and that data to
inform it are required. The high prevalence of S. aureus is
perhaps surprising, given data on incidence of causative
agents of BSI in sSA [38]. Though this could represent
true BSI, the possibility of a poor collection technique
or laboratory misidentification should be considered;
though it was possible to exclude coagulase-negative
Staphylococci from our analysis as likely contaminants,
determining whether S. aureus bacteraemia represented
true BSI was not possible with the available data. Des-
pite the fact that malaria diagnostic data is from studies
carried out in malaria-endemic countries—Malawi,
Uganda, Tanzania, and Zambia—malaria was less com-
mon than bacterial bloodstream infection, highlighting the
emerging importance of non-malarial aetiology of fever in
malaria-endemic areas. In the single study employing
PCR to describe sepsis aetiology beyond bloodstream
infection, CMV was extremely commonly isolated.
While it may cause illness in the immunocompro-
mised, CMV reactivation in critical illness is recog-
nised in high-income settings. Without viral testing in
a non-sepsis control group, the causal role of CMV is
therefore not clear [39]. Bacterial zoonoses were rare,
in contrast to sparse data from fever aetiology studies
from elsewhere in sSA [18], though no study carried
out reference-standard serological assays. Data on
antimicrobial resistance (AMR) patterns were lacking:
a single study with small numbers of patients, found
that Gram-negative third-generation cephalosporins
resistance (3GC-R) was significantly associated with
mortality. This, alongside data from across the con-
tinent suggesting that 3GC-R is an emerging problem
[38, 40, 41], highlights the need for high-quality
national and sub-national surveillance for AMR across
sSA to guide locally appropriate therapies.
The high prevalence of tuberculosis as a cause of
sepsis has significant implications for appropriate
antimicrobial therapy in sSA. Current sepsis pro-
tocols in high-income settings are based on rapid
administration of broad-spectrum antimicrobials to
cover common Gram-positive and Gram-negative
pathogens, rather than Mycobacteria. However, it is far
from clear how tuberculosis therapy should be used in this
patient population in sSA, and due to lack of data, it is not
possible to make any recommendations from the studies
we identified. Further studies are needed to guide clini-
cians in the best use of tuberculosis diagnostic tests or
empiric therapy in sepsis, as are pharmacokinetic studies
of tuberculosis therapy in the critically unwell.
We identified relatively few studies. Existing studies were
geographically restricted: Uganda contributed 8/15 studies,
for example, and Zambia 3/15. Several institutions—largely
tertiary referral centres—contributed multiple studies. Most
studies excluded surgical or obstetric patients. The studies
largely used a Sepsis-2 definition of sepsis and severe sepsis,
though with a number of modifications, making between-
study comparisons difficult. Development of easily appli-
cable sepsis definitions for low-resource settings—or prag-
matic modification of currently used screening scores such
as qSOFA—could significantly increase the generalisability
and utility of the evidence base in sSA.
There are weaknesses to our review, including that our
searches may have missed studies. We excluded studies
in preselected populations (in particular obstetric or
surgical sepsis) to maximise the generalisability of our
findings and minimise potential bias. These populations
were also excluded a priori by identified studies, leading to
lack of generalisability to surgical or pregnant patients.
Much of sSA is unrepresented, potentially leading to bias
from geographical restriction. Similarly, the results may
not generalise to sepsis in district hospitals, or primary
health care facilities, given the predominance of studies
from tertiary facilities. The heterogeneity in mortality
estimates means that the summary estimates should be
regarded with caution. As with all meta-regression, there
is the possibility of confounding or ecologic bias. Where it
was not possible to disaggregate data from identified
studies, we did not attempt to access individual
participant-level data. Assessing risk of bias for ob-
servational studies is difficult, with no recognised gold
standard. We chose to use the Newcastle-Ottawa score, a
frequently used tool, but one which has recognised
problems with reliability and validity [42, 43] and as such
our estimates of bias are likely to be under-estimates.
Conclusions
We have demonstrated that sepsis in sSA is dominated by
the high prevalence of advanced HIV, subjecting a younger
population to a high risk of sepsis of different microbial
aetiology to high-income/low-HIV settings. Short-term
outcomes are poor despite the younger age of sepsis
patients compared to high-income settings, whilst long-
term outcome data and morbidity data are absent. Data
on sepsis aetiology beyond bloodstream infection and
malaria are lacking though tuberculosis clearly plays an
important role, which has implications for selection of
appropriate antimicrobial therapy, though further studies
are needed to develop an evidence base for the treatment
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of tuberculosis in the critically ill. Development and
deployment of easily applicable sepsis definitions would
help improve our understanding of the burden of sepsis
in sSA and intervention studies aimed at the distinct
population in sSA are urgently needed.
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